Photodynamic antimicrobial chemotherapy (PACT) for the treatment of malaria, leishmaniasis and trypanosomiasis

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 1, 2011, Pages 1-10

  Baptista, M S ^a   Wainwright, M ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Chagas' disease; Leishmania; Photodynamic therapy; Photosensitisers; Singlet oxygen; Tropical diseases

Indexed keywords

AMINOLEVULINIC ACID; AMOTOSALEN; AMOTOSALEN (4' AMINOMETHYL 4,5',8 TRIMETHYLPSORALEN); AMPHOTERICIN B; BETA LACTAM DERIVATIVE; CHLOROQUINE; CRYSTAL VIOLET; MEPACRINE; METHYLENE BLUE; PAROMOMYCIN; PHTHALOCYANINE; QUINOLONE DERIVATIVE; RIBOFLAVIN; STIBOGLUCONATE SODIUM; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIMICROBIAL THERAPY; DISEASE TRANSMISSION; DISINFECTION; DRUG EFFICACY; DRUG STRUCTURE; ELECTRON TRANSPORT; ENERGY TRANSFER; HUMAN; LEISHMANIASIS; MALARIA; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW; TRYPANOSOMIASIS; UNSPECIFIED SIDE EFFECT; VECTOR CONTROL;

EID: 78751481968     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500141     Document Type: Review

References (60)

1. Engels D, Savioli L. Reconsidering the underestimated burden caused by neglected tropical diseases. Trends Parasitol 2006; 22: 363-366.
2. Croft SL. Public-private partnership: from there to here. Trans R Soc Trop Med Hyg 2005; 99 (Suppl 1): S9-S14.
3. Aruoma O. Free radicals in tropical diseases. Chur: Harwood Academic; 1993.
4. Packer L, Sies H. Singlet oxygen, UVA and ozone. In: Packer L (Editor), Methods in Enzymology. San Diego: Academic; 2000. p 319.
5. Wainwright M. Photodynamic antimicrobial chemotherapy (PACT). J Antimicrob Chemother 1998; 42: 13-28.
6. Wainwright M. Photosensitizers in biomedicine. 1st edn. Oxford: Wiley; 2009.
7. Raab O. Uber die wirking fluoreszierender stoffe auf infusorien. Zeits Biol 1900; 39: 524-546.
8. Nisbet EG, Sleep NH. The habitat and nature of early life. Nature 2001; 409: 1083-1091.
9. Triantaphylides C, Krischke M, Hoeberichts FA, Ksas B, Gresser G, Havaux M, et al. Singlet oxygen is the major reactive oxygen species involved in photooxidative damage to plants. Plant Physiol 2008; 148: 960-968.
10. Uchoa AF, Knox PP, Turchielle R, Seifullina NK, Baptista MS. Singlet oxygen generation in the reaction centers of Rhodobacter sphaeroides. Eur Biophys J 2008; 37: 843-850.
11. Foote CS. Mechanisms of photosensitized oxidation. There are several different types of photosensitized oxidation which may be important in biological systems. Science 1968; 162: 963-970.
12. Hryhorenko EA, Oseroff AR, Morgan J, Rittenhouse-Diakun K. Antigen specific and nonspecific modulation of the immune response by aminolevulinic acid based photodynamic therapy. Immunopharmacology 1998; 40: 231-240.
13. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006; 6: 535-545.
14. Junqueira HC, Severino D, Dias LG, Gugliotti M, Baptista MS. Modulation of the methylene blue photochemical properties based on the adsorption at aqueous micelle interfaces. Phys Chem Chem Phys 2002; 4: 2320-2328.
15. Tardivo JP, Del Giglio A, Oliveira CS, Gabrielli DS, Junqueira HC, Tada DB, et al. Methylene blue in photodynamic therapy: from basic mechanisms to clinical applications. Photodiagn Photodyn Ther 2005; 2/3: 175-191.
16. Gabrielli D, Belisle E, Severino D, Kowaltowski AJ, Baptista MS. Binding, aggregation and photochemical properties of methylene blue in mitochondrial suspensions. Photochem Photobiol 2004; 79: 227-232.
17. Ingraham MA. The bacteriostatic action of gentian violet and dependence on the oxidation-reduction potential. J Bacteriol 1933; 26: 573-598.
18. Do Campo R, Moreno SNJ, Cruz FS. Enhancement of the cytotoxicity of crystal violet against Trypanosoma cruzi in the blood by ascorbate. Molec Biochem Parasitol 1998; 27: 241-247.
19. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol B 1997; 39: 1-18.
20. Wainwright M. Photodynamic therapy: the development of new photosensitisers. Anticancer Agents Med Chem 2008; 8: 280-291.
21. Kessel D, Luo Y, Deng Y, Chang CK. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol 1997; 65: 422-426.
22. Henderson BW, Bellnier DA, Greco WR, Sharma A, Pandey RK, Vaughan LA, et al. An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res 1997; 57: 4000-4007.
23. Engelmann FM, Mayer I, Gabrielli DS, Toma HE, Kowaltowski AJ, Araki K, et al. Interaction of cationic meso-porphyrins with liposomes, mitochondria and erythrocytes. J Bioenerg Biomembr 2007; 39: 175-185.
24. Engelmann FM, Rocha SV, Toma HE, Araki K, Baptista MS. Determination of n-octanol/water partition and membrane binding of cationic porphyrins. Int J Pharm 2007; 329: 12-18.
25. Pavani C, Uchoa AF, Oliveira CS, Iamamoto Y, Baptista MS. Effect of zinc insertion and hydrophobicity on the membrane interactions and PDT activity of porphyrin photosensitizers. Photochem Photobiol Sci 2009; 8: 233-240.
26. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004; 5: 497-508.
27. Wainwright M, Amaral L. The phenothiazinium chromophore and the evolution of antimalarial drugs. Trop Med Int Health 2005; 10: 501-511.
28. Reddi E, Ceccon M, Valduga G, Jori G, Bommer JC, Elisei F, et al. Photophysical properties and antibacterial activity of meso-substituted cationic porphyrins. Photochem Photobiol 2002; 75: 462-470.
29. O'Neill J, Wilson M, Wainwright M. Comparative antistreptococcal activity of photobactericidal agents. J Chemother 2003; 15: 329-334.
30. Skripchenko A, Robinette D, Wagner SJ. Comparison of methylene blue and methylene violet for photoinactivation of intracellular and extracellular virus in red cell suspensions. Photochem Photobiol 1997; 65: 451-455.
31. Wagner SJ, Skripchenko A, Robinette D, Foley JW, Cincotta L. Factors affecting virus photoinactivation by a series of phenothiazine dyes. Photochem Photobiol 1998; 67: 343-349.
32. Greenwood B. Review: Intermittent preventive treatment - a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Trop Med Int Health 2006; 11: 983-991.
33. Wainwright M. Pathogen inactivation in blood products. Curr Med Chem 2002; 9: 127-143.
34. Goodrich RP, Platz MS, Martin CB. Use of visible light to reduce of wavelengths of 500 to 550 nm to reduce the number of pathogen in the blood and blood components. Patent No. US patent 7,498,156 B2. 2009.
35. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-885.
36. Ueber die wirkung des methylenblau bei malaria, Ehrlich P. Berl klin Wochens 1891; 39: 953-956.
37. Coleman R. The long-term contribution of dyes and stains to histology and histopathology. Acta Histochem 2006; 108: 81-83.
38. Meissner PE, Mandi G, Coulibaly B, Witte S, Tapsoba T, Mansmann U, et al. Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J 2006; 5: 84.
39. Wainwright M, Crossley KB. Methylene Blue - a therapeutic dye for all seasons? J Chemother 2002; 14: 431-443.
40. Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob Agents Chemother 1995; 39: 2671-2677.
41. Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991; 60: 207-213.
42. Zhao XJ, Lustigman S, Li YS, Kenney ME, Ben-Hur E. Structure-activity and mechanism studies on silicon phthalocyanines with Plasmodium falciparum in the dark and under red light. Photochem Photobiol 1997; 66: 282-287.
43. Young DG, Arias JR. Pan American Health Organization. Washington: Pan American Health Organization, Cuaderno Técnico No. 33; 1992.
44. Reithinger R, Davies CR. Is the domestic dog (Canis familiaris) a reservoir host of American cutaneous leishma niasis? A critical review of the current evidence. Am J Trop Med Hyg 1999; 61: 530-541.
45. Farrel JP. Leishmania. World class parasites. Vol. 4. Boston: Kluwer Academic; 2002.
46. Corradin SB, Mauel J. Phagocytosis of Leishmania enhances macrophage activation by IFN-gamma and lipopolysaccharide. J Immunol 1991; 146: 279-285.
47. de Freitas Balanco JM, Moreira ME, Bonomo A, Bozza PT, Amarante-Mendes G, Pirmez C, et al. Apoptotic mimicry by an obligate intracellular parasite downregulates macrophage microbicidal activity. Curr Biol 2001; 11: 1870-1873.
48. Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 1999; 189: 741-746.
49. Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 2007; 14: 1153-1169.
50. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19: 111-126.
51. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebocontrolled, randomized clinical trial. Clin Exp Dermatol 2006; 31: 634-637.
52. Kosaka S, Akilov OE, O'Riordan K, Hasan T. A mechanistic study of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis. J Invest Dermatol 2007; 127: 1546-1549.
53. Bristow C-A, Hudson R, Paget TA, Boyle RW. Potential of cationic porphyrins for photodynamic treatment of cutaneous leishmaniasis. Photodiag Photodyn Ther 2006; 3: 162-167.
54. Wagner SJ, Skripchenko A, Salata J, O'Sullivan AM, Cardo LJ. Inactivation of Leishmania donovani infantum and Trypanosoma cruzi in red cell suspensions with thiazole orange. Transfusion 2008; 48: 1363-1367.
55. Alves MJ, Rabinovitch M. Destruction of intracellular Trypanosoma cruzi after treatment of infected macrophages with cationic electron carriers. Infect Immun 1983; 39: 435-438.
56. Wainwright M, Mohr H, Walker WH. Phenothiazinium derivatives for pathogen inactivation in blood products. J Photochem Photobiol B 2007; 86: 45-58.
57. Gottlieb P, Margolis-Nunno H, Robinson R, Shen LG, Chimezie E, Horowitz B, et al. Inactivation of Trypanosoma cruzi trypomastigote forms in blood components with a Psoralen and Ultraviolet A light. Photochem Photobiol 1996; 63: 562-565.
58. Barbieri A. Sensibilizadores fluorescentes como larvicidas. Action fotodynamica de la luz. Riv Malariol 1928; 7: 456-463.
59. Ben Amor T, Jori G. Sunlight-activated insecticides: historical background and mechanisms of phototoxic activity. Insect Biochem Mol Biol 2000; 30: 915-925.
60. Ben Amor T, Bortolotto L, Jori G. Porphyrins and related compounds as photoactivatable insecticides. 3. Laboratory and field studies. Photochem Photobiol 2000; 71: 124-128.